Michael S Cowen1, Elena Krstew, Andrew J Lawrence. 1. Brain Injury and Repair Group, Howard Florey Institute, University of Melbourne, Royal Parade, Parkville, Victoria, Australia.
Abstract
RATIONALE: The development of mouse models of ethanol consumption and ethanol-seeking behavior is of particular importance in understanding the underlying mechanisms of drug abuse because these models can enable an analysis of an effect of specific genotype on drug-seeking behavior and the interaction of potential therapeutics with genotype. However, there are some limitations with present models, notably the inability to examine appetitive and consummatory behavior separately. MATERIALS AND METHODS: In the present study, C57BL/6 mice were trained to self-administer 10% ethanol in a modified operant protocol that allowed a clear delineation of consummatory and appetitive phases. The utility of this procedure was confirmed with the use of the metabotropic glutamate 5 (mGlu5) receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP). RESULTS: Limited-access consumption during the dark phase of the light-dark cycle with intermittent access (every second or third day) led to a high level of consumption by the mice. MTEP caused a dose-dependent decrease in both the consumption of ethanol and the appetitive response for ethanol. Furthermore, this effect was unrelated to any effect of MTEP on locomotor activity. CONCLUSIONS: The model provides a useful paradigm for examining both the appetitive and consummatory phases of ethanol consumption in mice; furthermore, the data indicate mGlu5 receptors are involved in both phases.
RATIONALE: The development of mouse models of ethanol consumption and ethanol-seeking behavior is of particular importance in understanding the underlying mechanisms of drug abuse because these models can enable an analysis of an effect of specific genotype on drug-seeking behavior and the interaction of potential therapeutics with genotype. However, there are some limitations with present models, notably the inability to examine appetitive and consummatory behavior separately. MATERIALS AND METHODS: In the present study, C57BL/6 mice were trained to self-administer 10% ethanol in a modified operant protocol that allowed a clear delineation of consummatory and appetitive phases. The utility of this procedure was confirmed with the use of the metabotropic glutamate 5 (mGlu5) receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP). RESULTS: Limited-access consumption during the dark phase of the light-dark cycle with intermittent access (every second or third day) led to a high level of consumption by the mice. MTEP caused a dose-dependent decrease in both the consumption of ethanol and the appetitive response for ethanol. Furthermore, this effect was unrelated to any effect of MTEP on locomotor activity. CONCLUSIONS: The model provides a useful paradigm for examining both the appetitive and consummatory phases of ethanol consumption in mice; furthermore, the data indicate mGlu5 receptors are involved in both phases.
Authors: A J Roberts; L H Gold; I Polis; J S McDonald; D Filliol; B L Kieffer; G F Koob Journal: Alcohol Clin Exp Res Date: 2001-09 Impact factor: 3.455
Authors: M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca Journal: J Neurosci Date: 2001-07-15 Impact factor: 6.167
Authors: Clyde W Hodge; Michael F Miles; Amanda C Sharko; Rebekah A Stevenson; Jennie R Hillmann; Veronique Lepoutre; Joyce Besheer; Jason P Schroeder Journal: Psychopharmacology (Berl) Date: 2005-11-15 Impact factor: 4.530
Authors: Jeffery J Anderson; Sara P Rao; Blake Rowe; Darlene R Giracello; Greg Holtz; Deborah F Chapman; Lida Tehrani; Margaret J Bradbury; Nicholas D P Cosford; Mark A Varney Journal: J Pharmacol Exp Ther Date: 2002-12 Impact factor: 4.030
Authors: A Pilc; A Kłodzińska; P Brański; G Nowak; A Pałucha; B Szewczyk; E Tatarczyńska; E Chojnacka-Wójcik; J M Wierońska Journal: Neuropharmacology Date: 2002-08 Impact factor: 5.250
Authors: Max E Joffe; Samuel W Centanni; Anel A Jaramillo; Danny G Winder; P Jeffrey Conn Journal: ACS Chem Neurosci Date: 2018-06-08 Impact factor: 4.418
Authors: Justin T Gass; Megan P H Osborne; Noreen L Watson; Jordan L Brown; M Foster Olive Journal: Neuropsychopharmacology Date: 2008-09-17 Impact factor: 7.853
Authors: Debra K Cozzoli; Moriah N Strong-Kaufman; Michelle A Tanchuck; Joel G Hashimoto; Kristine M Wiren; Deborah A Finn Journal: Alcohol Clin Exp Res Date: 2013-10-29 Impact factor: 3.455